Grifols Yönetim

Yönetim kriter kontrolleri 2/4

Grifols CEO'su Nacho Abia Buenache, Apr2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.014% doğrudan sahiptir ve bu hisselerin değeri € 888.05K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.8 yıl ve 7 yıldır.

Anahtar bilgiler

Nacho Abia Buenache

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.01%
Yönetim ortalama görev süresi	6.8yrs
Yönetim Kurulu ortalama görev süresi	7yrs

Son yönetim güncellemeleri

Recent updates

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

May 21

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Apr 20

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Mar 01

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Oct 20

Is Grifols (BME:GRF) A Risky Investment?

Aug 03

CEO

Nacho Abia Buenache (56 yo)

less than a year

Görev süresi

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jose Ignacio Abia Buenache	CEO & Director	less than a year	Veri yok	0.014% € 888.0k
Alfredo Guerra	CFO & VP	17.8yrs	Veri yok	Veri yok
Lluis Gomez	Senior Vice President of Strategy & COO Office	no data	Veri yok	Veri yok
Nuria Lapeña	VP of Corporate Treasury	no data	Veri yok	Veri yok
David Bell	Chief Corporate Development	21.8yrs	Veri yok	0.0029% € 191.1k
Maria Teresa-Rioné Llano	Chief Communications Officer	6.8yrs	Veri yok	0.00078% € 50.7k
Camille Alpi	Chief Human Resources & Talent Officer	less than a year	Veri yok	Veri yok
Vicente Blanquer Torre	Chief Quality Officer	31.8yrs	Veri yok	Veri yok
Sergio Adell	President of Commercial Tech Support	5.8yrs	Veri yok	Veri yok
Víctor Grifols Deu	Executive Director	no data	€1.04m	0.016% € 1.0m
Miguel Montblanch	President of Commercial Operations Support	12.8yrs	Veri yok	Veri yok
Daniel Coit	Chief Industrial Services Officer	5.8yrs	Veri yok	Veri yok

6.8yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: GRF 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jose Ignacio Abia Buenache	CEO & Director	less than a year	Veri yok	0.014% € 888.0k
Víctor Grifols Deu	Executive Director	8.5yrs	€1.04m	0.016% € 1.0m
Iñigo Mardones	Independent Director	9.5yrs	€150.00k	Veri yok
Thomas Glanzmann	Non-Executive Chairman	18.6yrs	€1.90m	0.029% € 1.9m
Juan Twose Roura	Member of the Advisory Committee	9.8yrs	€380.00k	Veri yok
Raimon Grifols Roura	Vice-Chairman	9.5yrs	€1.04m	0.0060% € 393.3k
Tomas Daga Gelabert	Independent External Director	24.6yrs	Veri yok	0.045% € 2.9m
Albert Coma-Cros	Proprietary Director	less than a year	Veri yok	0.0097% € 631.3k
Enriqueta Font	Independent Director	5.5yrs	€125.00k	Veri yok
Montserrat Abellana	Lead Independent Director	2.4yrs	€63.00k	Veri yok
Susana Gonzalez Rodriguez	Independent Director	2.4yrs	€63.00k	Veri yok
Anne-Catherine Berner	Independent Director	less than a year	Veri yok	Veri yok

7.0yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: GRF 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7 yıldır).

Grifols Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Recent updates

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Investor sentiment improves as stock rises 15%

Second quarter 2024 earnings: EPS misses analyst expectations

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Investor sentiment deteriorates as stock falls 16%

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols (BME:GRF) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

New minor risk - Earnings quality

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

First quarter 2024 earnings released

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Price target decreased by 7.1% to €17.40

Are Investors Undervaluing Grifols, S.A. (BME:GRF) By 32%?

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Now 21% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 23%

Consensus EPS estimates fall by 13%

Grifols, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings: Revenues in line with analyst expectations

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Revenues Working Against Grifols, S.A.'s (BME:GRF) Share Price Following 27% Dive

Does Grifols (BME:GRF) Have A Healthy Balance Sheet?

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 12%

Benign Growth For Grifols, S.A. (BME:GRF) Underpins Its Share Price

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

New major risk - Share price stability

Here's Why Grifols (BME:GRF) Is Weighed Down By Its Debt Load

Consensus EPS estimates fall by 16%

Third quarter 2023 earnings released

Consensus EPS estimates increase by 45%

Is Grifols, S.A. (BME:GRF) Expensive For A Reason? A Look At Its Intrinsic Value

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Consensus EPS estimates increase by 46%

Consensus EPS estimates fall by 28%

Is Grifols (BME:GRF) A Risky Investment?

New major risk - Financial position

Second quarter 2023 earnings released

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş